New

A method using ultrasound for enhancing and controlling transbuccal permeation of a molecule, including drugs, antigens, vitamins, inorganic and organic compounds, and various combinations of these substances, through the buccal membranes and into the circulatory sys- tem. The frequency and intensity of ultrasonic energy which is applied, and the length of time of exposure are determined according to the loca- tion and nature of the buccal membrane and the substance to be infused. Levels of the infused molecules in the blood and urine measured over a period of time are initially used to determine under what conditions optimum transfer occurs. In a variation of the method, whereby ul- trasound is applied directly to the compound and site where the compound is to be infused through the buccal membranes, the compound can be placed within a delivery device. In one variation, the ultrasound can control release both by direct interaction with the compound and membrane but also with the delivery device. In another variation, the delivery device helps to modulate release and infusion rate. The com- pound can also be administered in combination with a chemical agent which alters permeability of the buccal membrane, thereby aiding infusion of the compound into the circulatory system.

4948725

N O V E L T Y P E VI B A C T E R I A L F C R E C E P T O R S

Michael D P Boyle assigned to University of Florida Research Foundation Inc

Novel Fc receptors, denoted type VI, are dis- closed as reacting with rat immunoglobulins with a reasonable affinity. These receptors, or the microorganisms which produce them, are useful in immunoassays.

4948726

E N Z Y M E I M M U N O A S S A Y B A S E D O N M E M B R A N E S E P A R A T I O N

O F A N T I G E N - A N T I B O D Y C O M P L E X E S

Claude C Longoria

An enzyme immunoassay based on membrane separation of antigen-antibody complexes wherein human or animal body fluid specimens containing an antigen are mixed with an enzyme-

Patents

conjugated antibody specific for the antigen un- der test. Following incubation the antigen- antibody-conjugate mixture is passed through a filter membrane having an electrostatic charge providing an affinity for retaining antigen- antibody-conjugate complexes while not retaining free antibody-conjugate. Following washing of the filter membrane to remove free antibody-conjugate remaining thereon an en- zyme substrate-chromogen reagent solution is applied to the filter membrane, which reacts with filter-bound antibody-conjugate and develops a visible or fluorogenic color indicative of the pre- sence of antibody-conjugate.

4948738

M O N O C L O N A L A N T I B O D I E S T O G A M M A - I N T E R F E R O N ,

H Y B R I D O M A S P R O D U C I N G S U C H A N T I B O D I E S , A N D K I T

F O R U S I N G S U C H A N T I B O D I E S

Jacques Banchereau, Odile Djossou, John Wij- denes, Helgra/e/ ne Cabrillat, Catherine Favre, Ecully, France assigned to Laboratoires UNICET

Monoclonal antibodies to gamma-interferon and hybridomas producing such antibodies are disclosed. The antibodies are preferably of the immunoglobulin subclass IgGl, kappa, and do not bind to interferon- alpha2.

4948793

T R E A T M E N T O F A U T O I M M U N E D I S E A S E S W I T H T H E

M O R P H O L I N O E T H Y L E S T E R O F M Y C O P H E N O L I C ACID, A N D

D E R I V A T I V E S T H E R E O F

Anthony Allison, Elsie Eugui, Peter H Nelson, Chee-Liang L Gu, William Lee assigned to Syn- tex (U S A ) Inc

The compounds and pharmaceutical composi- tions of Formula A, wherein Z is hydrogen or - C(O)R, Y is hydrogen or morpholinoethyl, and where R is lower alkyl or aryl, and the pharma- ceutically acceptable salts thereof, are useful as immunosuppressive agents, particularly for treatment of allograft rejection, especially in- cluding cardiac allograft rejection, pancreatic al- lograft rejection and renal allograft rejection, and for treating autoimmune diabetes. See Pa- tent for Chemical Structure (Formula A)

CIMID 14/I--E